This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Brazilian Clinical Research Network | |
|---|---|
| Name | Brazilian Clinical Research Network |
| Focus | Clinical research |
Brazilian Clinical Research Network is a national consortium linking hospitals, universities, and research institutes to coordinate biomedical trials and translational research across Brazil. It connects clinical centers, regulatory agencies, and funding bodies to accelerate trials in infectious diseases, oncology, cardiology, and neglected tropical diseases. The Network engages with international consortia, ethics committees, and pharmaceutical partners to implement multicenter randomized controlled trials and observational studies.
The Network's mission aligns with mandates set by Ministry of Health (Brazil), Oswaldo Cruz Foundation, Fiocruz, Butantan Institute, Universidade de São Paulo, and Universidade Federal do Rio de Janeiro to strengthen capacity for clinical trials, patient safety, and evidence-based interventions. Its strategic priorities reflect frameworks from World Health Organization, Pan American Health Organization, European Medicines Agency, U.S. Food and Drug Administration, and International Committee of Medical Journal Editors for trial registration, reporting, and good clinical practice. The Network emphasizes collaboration among Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Instituto Nacional de Infectologia Evandro Chagas, Instituto de Pesquisas Clínicas, and regional referral centers in Amazonas, Bahia, and Rio Grande do Sul.
Origins trace to initiatives supported by CNPq, CAPES, and Programa de Apoio ao Desenvolvimento Institucional do Sistema Único de Saúde during the early 2000s, following precedents set by cooperative groups such as Brazilian Society of Infectious Diseases and Brazilian Society of Clinical Oncology. Milestones include alignment with the Conselho Nacional de Saúde ethics frameworks, adoption of trial registries like ClinicalTrials.gov and the Brazilian Registry of Clinical Trials (ReBEC), and participation in emergency responses during the Zika virus epidemic in Brazil, the COVID-19 pandemic, and outbreaks of dengue fever in Brazil. The Network expanded through collaborations with World Bank, Bill & Melinda Gates Foundation, Wellcome Trust, and bilateral cooperation with United Kingdom Research and Innovation, National Institutes of Health (USA), and European Commission programs.
Governance draws upon models used by Instituto Nacional de Câncer, Brazilian National Research Ethics Commission, and regional health secretariats, featuring a board with representatives from Ministry of Health (Brazil), Fiocruz, ANVISA (Brazilian Health Regulatory Agency), academic institutions like Universidade Estadual de Campinas, and patient advocacy groups such as Associação Paulista de Medicina. The Network maintains scientific steering committees mirroring structures at NIH Clinical Center, Wellcome Sanger Institute, and Institut Pasteur, and operational cores for data management influenced by European Clinical Research Infrastructure Network (ECRIN) and Global Alliance for Genomics and Health. Institutional review processes follow protocols from Research Ethics Committees (CEP), coordinated with Conselho Nacional de Saúde oversight.
Programs encompass multicenter randomized controlled trials, platform trials, adaptive designs, and observational cohort studies across specialties tied to Instituto do Coração (InCor), Hospital Israelita Albert Einstein, Instituto de Medicina Tropical de São Paulo, and regional university hospitals. Trial areas include vaccines and therapeutics for Zika virus, COVID-19, influenza, HIV/AIDS, Chagas disease, leishmaniasis, and oncology studies in partnership with Sociedade Brasileira de Oncologia Clínica. Methodological frameworks reference standards from CONSORT, SPIRIT, and Good Clinical Practice guidelines used by EMA and FDA. Data platforms integrate technologies comparable to REDCap and biobanks modeled on National Cancer Institute (United States) repositories.
The Network partners with international institutions such as World Health Organization, Pan American Health Organization, University of Oxford, Imperial College London, Johns Hopkins University, Harvard T.H. Chan School of Public Health, and LSHTM. Industry collaborations involve multinational pharmaceutical firms and local manufacturers including Instituto Butantan vaccine programs and biotechnology startups incubated by Agência Brasileira de Inovação. Regional alliances include ties to Mercosur health initiatives, Latin American research networks like Red Latinoamericana de Investigación en Salud, and clinical trial consortia coordinated with PAHO/WHO Collaborating Centres.
Funding streams combine grants from CNPq, CAPES, FINEP, state research foundations such as FAPERJ, FAPESP, and philanthropic support from Bill & Melinda Gates Foundation and Wellcome Trust. Emergency funding during crises has been sourced through mechanisms linked to Ministry of Health (Brazil), World Bank emergency loans, and international rapid-response funds administered via PAHO. Infrastructure investments emulate models used by Johns Hopkins Medicine and Mayo Clinic for clinical research units, with training programs supported by exchanges with NIH and fellowships administered in collaboration with Universidade de São Paulo.
Notable contributions include coordinated trials that informed national responses to the Zika virus epidemic in Brazil and evidence from multicenter COVID-19 therapeutics and vaccine studies aligned with global trials led by RECOVERY Trial collaborators. Publications have appeared in journals associated with The Lancet, New England Journal of Medicine, JAMA, and BMJ, and findings have influenced policy decisions within Ministry of Health (Brazil) and regulatory guidance from ANVISA (Brazilian Health Regulatory Agency). The Network has bolstered capacity at institutions such as Fiocruz, Butantan Institute, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, and universities across Brazil, while fostering partnerships with Oxford University, NIH, and World Health Organization for future multicenter trials.
Category:Medical research organizations in Brazil